Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
As blogger Dann Wonser’s treatment options dwindled, the FDA is about to approve a new med for his lung cancer.
Two new clinical trials compare Retevmo (selpercatinib) with other standard treatments for tumors with changes in the RET gene.
Better outcomes were achieved with combinations of experimental new drugs targeting common and rare tumour mutations.
Repotrectinib led to tumor shrinkage in 79% of patients who had not previously used a tyrosine kinase inhibitor.
Adding checkpoint inhibitors to chemotherapy before surgery and continuing them alone afterward reduces the risk of recurrence and death.
Annual screening is now recommended for current and former smokers ages 50 to 80, regardless of whether they quit.
People who received the targeted therapy after surgery were less likely to experience recurrence or brain metastasis.
The checkpoint inhibitor is now indicated for pre- and post-surgery treatment of Stage II or III non-small-cell lung cancer.
Other studies focused on bladder cancer, prostate cancer and liquid biopsies.
“I’ve gotten pretty good at bouncing back,” writes Dann Wonser after getting kicked out of a cancer clinical trial and facing chemo.
Immune checkpoint inhibitors have revolutionized lung cancer treatment, but the optimal duration of therapy is unknown.
Tumor-treating fields therapy uses electricity delivered via a wearable device to kill cancer cells.
Osimertinib led to a 51% improvement in survival, but some say the placebo group did not receive adequate treatment.
New results from the AEGEAN clinical trial offer good news to people with non-small cell lung cancer.
Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.
HIV-positive people who use checkpoint inhibitors have side effects, response rates and survival comparable to those of HIV-negative people.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.